Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy

Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy

Abstract Background Delamanid and bedaquiline are two of the most recently developed antituberculosis (TB) drugs that have been extensively studied in patients with multidrug-resistant TB. There is currently a need for more potent, less-toxic drugs with novel mechanisms of action that can be used in...

Full description

Bibliographic Details
Main Authors: Rodney Dawson, Andreas H. Diacon, Simbarashe Takuva, Yongge Liu, Bo Zheng, Vatsala Karwe, Jeffrey Hafkin
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Trials
Subjects:
Antituberculosis agent
Bedaquiline
Delamanid
DprE1 inhibitor
Drug-sensitive tuberculosis
Quabodepistat
Online Access:https://doi.org/10.1186/s13063-024-07912-5

Internet

https://doi.org/10.1186/s13063-024-07912-5

Similar Items